Talzenna is a cancer medicine used on its own to treat a type of breast cancer (HER2-negative with BRCA mutations) that has spread beyond the original site (locally advanced or metastatic), in patients who have been treated with certain medicines which have stopped working or when these medicines are not suitable. Talzenna is also used together with another cancer medicine, enzalutamide, to treat adults who have castration-resistant prostate cancer that has spread to other parts of the body (metastatic) and who cannot have chemotherapy. Castration-resistant means that the disease has worsened despite treatment to lower testosterone levels, including surgical removal of the testes. Talzenna contains the active substance talazoparib
Therapeutic Indication
### Therapeutic indication Treatment with Talzenna should be initiated and supervised by a physician experienced in the use of anticancer medicinal products. **Patient selection** Breast cancer: Patients should be selected for the treatment of breast cancer with Talzenna based on the presence of deleterious or suspected deleterious germline BRCA mutations determined by an experienced laboratory using a validated test method. Genetic counselling for patients with BRCA mutations should be performed according to local regulations, as applicable. Prostate cancer: There is no requirement for tumour mutation testing for selection of patients with mCRPC for treatment with Talzenna.
Therapeutic Area (MeSH)
ATC Code
L01XK04
ATC Item
talazoparib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| talazoparib | N/A | 他拉唑帕利 |
EMA Name
Talzenna
Medicine Name
Talzenna
Aliases
N/A
